$522.7M in CY2024 Part D spend157K claims · 23K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Omalizumab used for?
XOLAIR is an anti-IgE antibody indicated for: Moderate to severe persistent asthma in adults and pediatric patients 6 years of age and older with a positive skin test or in vitro reactivity to a pe....
Is there a generic for Omalizumab?
No. Omalizumab is brand-only with no generic equivalents currently in market.
How much does my plan pay for Omalizumab?
NADAC pricing data not currently available for this drug.
Is Omalizumab on the FDA shortage list?
No. Omalizumab is not currently on the FDA Drug Shortage Database.
5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.